{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-005549","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.703241+00:00","generated_at":"2026-06-18T17:56:40.531481+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Xenon reports FY2022 net loss of $125.4M; cash $720.8M; XEN1101 Phase 3 ongoing","bullets":["Net loss of $125.4M for FY2022 vs $78.9M in 2021; Q4 net loss $37.4M.","Revenue $9.4M for FY2022 vs $18.4M in 2021; no Q4 revenue.","Cash and marketable securities $720.8M as of Dec 31, 2022; sufficient into 2026.","XEN1101 Phase 3 epilepsy trials (X-TOLE2, X-TOLE3, X-ACKT) enrolling; topline MDD data expected Q3 2023.","Neurocrine partner Phase 2 FOS data expected H2 2023; XEN496 Phase 3 EPIK completion expected 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-005549","json":"https://secwatch.observer/filing/0000950170-23-005549.json","markdown":"https://secwatch.observer/filing/0000950170-23-005549.md","text":"https://secwatch.observer/filing/0000950170-23-005549.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023005549/0000950170-23-005549-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023005549/xene-20230301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T17:56:40.531481+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ab1874f0e91dae23c692ff216307ec3e5b21e6a","claim":"Xenon Pharmaceuticals Inc. reported financial results for the year ended December 31, 2022.","evidence_excerpt":"On March 1, 2023, Xenon Pharmaceuticals Inc. (the “Company”) announced via press release the Company’s financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023005549/0000950170-23-005549-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}